← Eichor
Condition: Advanced Solid Tumors Or Lymphomas Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Solid Tumors Or Lymphomas

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
Phase 1 · 1 location(s) · L & L Bio Co., Ltd., Ningbo, China · NCT05357651Intratumoral CAN2109 in Subjects With Solid Tumors
Phase 1 · 1 location(s) · Canwell Biotech Limited · NCT06332430An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Phase 1 · 7 location(s) · FBD Biologics Limited · NCT06487624A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Ac
Phase 1/Phase 2 · 74 location(s) · Nuvalent Inc. · NCT05384626Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT06073938Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT05631886A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Phase 1 · 4 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT05341557Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/Phase 2 · 11 location(s) · OSE Immunotherapeutics · NCT05751798A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/Phase 2 · 68 location(s) · Turning Point Therapeutics, Inc. · NCT04094610Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Phase 1 · 4 location(s) · InSilico Medicine Hong Kong Limited · NCT06445517A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan
Phase 1/Phase 2 · 7 location(s) · Merck Sharp & Dohme LLC · NCT07302347First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Phase 1 · 10 location(s) · EpimAb Biotherapeutics (Suzhou)Co., Ltd. · NCT05607498Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT06292208Evaluate the Safety and Clinical Activity of HH2853
Phase 1/Phase 2 · 25 location(s) · Haihe Biopharma Co., Ltd. · NCT04390737SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Phase 1/Phase 2 · 1 location(s) · University of California, San Diego · NCT07222631A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Phase 1 · 8 location(s) · FBD Biologics Limited · NCT05892718TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/Phase 2 · 1 location(s) · Tyligand Bioscience (Shanghai) Limited · NCT05842785A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNO
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT02332668VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · 15 location(s) · VM Oncology, LLC · NCT03556228Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and So
Phase 1 · 1 location(s) · Lantern Pharma Inc. · NCT06132503
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.